Arena Pharmaceuticals posted a wider-than-expected loss in the fourth quarter, as the biopharmaceutical company’s sales were almost negligible. Shares declined about 2.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released second-quarter results and hosted a quarterly call, where management provided a corporate update as well as an update on clinical …
